Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Legat, FJ; Hofer, A; Wackernagel, A; Salmhofer, W; Quehenberger, F; Kerl, H; Wolf, P.
Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis
ARCH DERMATOL. 2007; 143(8): 1016-1022.
Doi: 10.1001/archderm.143.8.1016
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Legat Franz
- Wolf Peter
- Co-authors Med Uni Graz
- Gruber-Wackernagel Alexandra
- Hofer Angelika
- Kerl Helmut
- Quehenberger Franz
- Salmhofer Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To determine whether the addition of 311-nm narrowband UV-B (NB UV-B) phototherapy accelerates and improves the therapeutic efficacy of alefacept, a biological antipsoriatic drug approved for the treatment of moderate to severe psoriasis. Randomized half-body comparison study. Ambulatory section of a university hospital photodermatology unit. Fourteen patients with moderate to severe psoriasis. All patients were treated with 7.5 mg of intravenous alefacept once weekly for 12 weeks. Three times each week, a randomly selected body half (left or right) was treated with NB UV-B light until complete remission, defined as a reduction in the Psoriasis Area Severity Index (PASI) to 3 or lower, was achieved on the irradiated body half. Modified PASI, self-assessed visual analogue scale rating of skin lesions, and self-assessed therapeutic efficacy. After 12 weeks of treatment, the mean PASIs on UV-irradiated and nonirradiated body halves were significantly reduced by 81% and 62%, respectively (P < .001). From week 3 to week 12, the mean PASI was significantly lower on UV-irradiated body halves than on nonirradiated body halves (P < .001). At week 12, PASI reductions of greater than 75% had been achieved significantly more often on UV-irradiated body halves (86%, 12 of 14) than on nonirradiated body halves (43%, 6 of 14), and complete remission had been achieved significantly more often on UV-irradiated body halves (43%, 6 of 14) than on nonirradiated body halves (0 of 14) (McNemar test P = .03). In this randomized half-side comparison of alefacept with and without phototherapy for psoriasis, alefacept with NB UV-B phototherapy accelerated and improved the clearance of psoriasis. This suggests a promising future for this combination as antipsoriatic therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Combined Modality Therapy -
- Dermatologic Agents - administration & dosage
- Female -
- Follow-Up Studies -
- Humans -
- Male -
- Middle Aged -
- Prospective Studies -
- Psoriasis - drug therapy
- Psoriasis - pathology
- Psoriasis - radiotherapy
- Recombinant Fusion Proteins - administration & dosage
- Treatment Outcome -
- Ultraviolet Therapy -